CAR-T therapy aimed at tough kidney disease in kids — but trial never started
NCT ID NCT06842589
First seen Jun 23, 2026 · Last updated Jun 23, 2026
Summary
This was a planned early-stage trial to test whether anti-CD19 CAR-T cells could safely help children with multi-drug resistant nephrotic syndrome, a serious kidney condition. The study was withdrawn before any patients were enrolled, so no data on safety or effectiveness were collected. The approach aimed to use engineered immune cells to target and possibly calm the overactive immune system driving the disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CAR-T CELL THERAPY are added.
Genom att skicka in godkänner du våra Användarvillkor
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
anti-CD19 CAR-T cells
What this could lead to
If this approach had been tested and worked, it could point toward a new treatment option for children with hard-to-treat nephrotic syndrome.
What could go wrong
This trial was withdrawn before enrolling any participants, so no results are available. CAR-T therapy carries serious risks like cytokine release syndrome and infections, and its use in kidney disease is very early and uncertain.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.